Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus

Tousoulis, Dimitris; Antoniades, Charalambos; Vasiliadou, Carmen; Kourtellaris, Pantelis; Koniari, Katerina; Marinou, Kyriakoula; Charakida, Marietta; Ntarladimas, Ioannis; Siasos, Gerasimos; Stefanadis, Christodoulos

doi:10.1136/hrt.2006.093112

Cited by 68 publications

(43 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tsunekawa 124 27 Cerivastatin/placebo 3 days FMD + Tan 125 80 Atorvastatin/placebo 6 FMD + Ceriello 126 30 Simvastatin/placebo 3-6 days/+ 3 FMD + Ceriello 127 20 Atorvastatin/irbesartan/placebo 1 wk FMD + Economides 128 40 Atorvastatin/placebo 3 FMD ns Beishuizen 129 250 Cerivastatin replaced by simvastatin 24 FMD ns Van Venrooij 130 133 Atorvastatin 10 mg/atorvastatin 80 mg 7.5 FMD ns Tantikosoom 132 42 Atorvastatin/placebo 7.5 FMD ns Balletshofer 131 58 Cerivastatin/placebo 3 FMD ns Tousoulis 69 41…”

Section: Lipid-regulating Agents Statinsmentioning

confidence: 98%

Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus

Hamilton

Chew

Watts

2007

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Endothelial dysfunction is universal in diabetes, being intimately involved with the development of cardiovascular disease. The pathogenesis of endothelial dysfunction in diabetes is complex. It is initially related to the effects of fatty acids and insulin resistance on 'uncoupling' of both endothelial nitric oxide synthase activity and mitochondrial function. Oxidative stress activates protein kinase C (PKC), polyol, hexosamine and nuclear factor kappa B pathways, thereby aggravating endothelial dysfunction. Improvements in endothelial function in the peripheral circulation in diabetes have been demonstrated with monotherapies, including statins, fibrates, angiotensin-converting enzyme (ACE) inhibitors, metformin and fish oils. These observations are supported by large clinical end point trials. Other studies show benefits with certain antioxidants, L-arginine, folate, PKC-inhibitors, peroxisome proliferator activated receptor (PPAR)-alpha and -gamma agonists and phosphodiesterase (PDE-5) inhibitors. However, the benefits of these agents remain to be shown in clinical end point trials. Combination treatments, for example, statins plus ACE inhibitors and statins plus fibrates, have also been demonstrated to have additive benefits on endothelial function in diabetes, but there are no clinical outcome data to date. Measurement of endothelial dysfunction in cardiovascular research can provide fresh opportunities for exploring the mechanism of benefit of new therapeutic regimens and for planning and designing large clinical trials.

show abstract

Section: Lipid-regulating Agents Statinsmentioning

confidence: 98%

Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus

Hamilton

Chew

Watts

2007

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

show abstract

“…No changes were seen in other biomarkers. Type 2 DM patients without macroangiopathy [68] Atorvastatin ( Cross-over study [n = 45] Simvastatin alone (20 mg/day) Ramipril (5-10 mg/day) and simvastatin Ramipril alone Each treatment for 2 months with a washout period of 2 months.…”

Section: Can Antioxidant Supplementation Decrease Oxidative Stress Inmentioning

confidence: 99%

Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?

Choi

2017

Redox Report

View full text Add to dashboard Cite

Objectives: This is a narrative review, investigating the antioxidant properties of drugs used in the management of diabetes, and discusses whether these antioxidant effects contribute to, confound, or conceal the effects of antioxidant therapy. Methods: A systematic search for articles reporting trials, or observational studies on the antioxidant effect of drugs used in the treatment of diabetes in humans or animals was performed using Web of Science, PubMed, and Ovid. Data were extracted, including data on a number of subjects, type of treatment (and duration) received, and primary and secondary outcomes. The primary outcomes were reporting on changes in biomarkers of antioxidants concentrations and secondary outcomes were reporting on changes in biomarkers of oxidative stress. Results: Diabetes Mellitus is a disease characterized by increased oxidative stress. It is often accompanied by a spectrum of other metabolic disturbances, including elevated plasma lipids, elevated uric acid, hypertension, endothelial dysfunction, and central obesity. This review shows evidence that some of the drugs in diabetes management have both in vivo and in vitro antioxidant properties through mechanisms such as scavenging free radicals and upregulating antioxidant gene expression. Conclusion: Pharmaceutical agents used in the treatment of type 2 diabetes has been shown to exert an antioxidant effect..

show abstract

“…Statins exert anti-inflammatory effects in patients with DM [27][28][29][30]. The present study indicates that combined treatment with metformin plus atorvastatin leads to a) a significant reduction of TNF-α -levels and b) a reduction of TNF-α levels post-glucose loading.…”

Section: Effects Of Atorvastatin On Tnf-a Levels In Patients With Diamentioning

confidence: 66%

Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus

Tousoulis¹,

Koniari²,

Antoniades³

et al. 2011

International Journal of Cardiology

View full text Add to dashboard Cite

Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus

Cited by 68 publications

References 6 publications

Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus

Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus

Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?

Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus

Contact Info

Product

Resources

About